The Impact and Long-Term Potential of Olaratumab in Soft Tissue Sarcoma
2 Views
administrator
07/18/23
Symantha Melemed, PhD, global product team lead, Oncology Business Unit, Eli Lilly & Company, discusses the impact of the FDA approval of olaratumab (Lartruvo) and its long-term potential in the field of sarcoma.
-
Category
Show more
Facebook Comments
No comments found